Exhibition and Partnership

Stroke is a leading cause of death worldwide and approximately 87% of strokes are ischemic strokes. The ability to access the clot site efficiently is paramount to achieving good patient outcomes. Recent trials suggest current technology achieves 40 – 50% first pass effect, suggesting opportunity to improve.
Engineering principles govern that catheter inner diameter (ID) is an exponential determinant of flow through its lumen, however conventional catheter reinforcement limits the ability to track large catheters through tortuosity. The Broadway system was developed to significantly improve the technical limitations of conventional catheter reinforcements and allows engineers to better balance the competing engineering requirements that make navigation of super bore catheters distally challenging.
Engineering principles are reported, the Broadway system and its laser cut hypotube reinforcement is described. The engineering performance of Echo and Broadway catheters versus relevant controls is reported along with the early clinical performance of Broadway system versus controls.

Background: Venous sinus stenting has increasingly emerged as an effective treatment option for patients with idiopathic intracranial hypertension (IIH) and pulsatile tinnitus (PT) associated with symptomatic venous sinus stenosis. However, current interventions primarily rely on off-label stents originally designed for other vascular indications, which may limit procedural performance and anatomical compatibility.
Objective: The newly developed SILANCE® Stent incorporates a low-profile 3F microcatheter delivery system, atraumatic ends, reduced metal coverage, and enhanced flexibility. These features facilitate navigation through tortuous venous anatomy and support precise deployment within the cerebral venous sinuses. By addressing key limitations of commonly used carotid stents, the device is intended to simplify the procedure, improve procedural safety, and promote effective restoration of venous outflow.
Conclusion: The SILANCE® Stent represents a dedicated technological advancement in venous sinus stenting and has the potential to improve the treatment of patients with IIH and PT caused by symptomatic venous sinus stenosis.

The role of endovascular thrombectomy in medium vessel occlusions (MeVOs) remains under active investigation. While recent randomized trials have shown mixed results, emerging evidence suggests selected patients, particularly those with eloquent territory occlusions, may benefit from thrombectomy. Conventional outcome measures such as the modified Rankin Scale may not fully capture deficits in language, cognition, vision, or fine motor function, highlighting the need for improved patient selection.
The growing treatment of MeVOs also underscores the importance of devices that combine effective clot retrieval with atraumatic navigation through small, tortuous vessels. The NeVa™ 3 mm stent retriever extends Vesalio’s Drop Zone™ Technology into a lower-profile device compatible with 0.017-inch microcatheters, enabling access to distal and challenging anatomy.
This presentation will review the device design and summarize preliminary multicenter experience from the first 20–40 cases, focusing on navigability, deliverability, procedural success, safety, and practical insights into thrombectomy technique and patient selection.

Royal London Hospital redesigned their stroke care pathway, an initiative aimed at improving outcomes and reducing long-term disability for stroke patients in the UK. The project has involved close collaboration with clinical and operational teams at Royal London Hospital to better understand the practical challenges of stroke care delivery. Through immersive workshops and in-depth interviews with clinical staff, they mapped the ischemic stroke pathway, identifying key workflow pain points and systemic barriers, and reflecting how national stroke statistics play out in everyday clinical settings. Improving the stroke pathway is not only a clinical priority, but also a strategic step toward shaping the future of stroke care across the UK. By identifying challenges, the initiative is looking at potential opportunities to streamline care delivery, reduce treatment delays and enhance experiences for both patients and staff. Insights gathered are now sparking conversations about redesigning the workflow and integrating technology that has the potential to accelerate access to life-saving treatments and potentially better rehabilitation outcomes.

Obtura® is a third-generation EVOH/DMSO liquid embolic agent. It is best known for its defining innovation: intentional, progressive post-procedural radiopacity loss. However, its clinical value extends beyond visibility.
This presentation examines the technical properties that shape procedural performance: a predictable precipitation profile and the absence of sedimentation, which removes the need for shaking and allows longer, more controlled injections. Consistent forward penetration reaches residual shunts and distal nidus. Built on a familiar DMSO-compatible platform, Obtura® offers refined control during complex injections.

Wide-neck intracranial aneurysms remain technically challenging to treat with conventional coiling because of the risk of coil instability or protrusion into the parent artery. Stent-assisted embolization provides a supporting scaffold across the aneurysm neck, facilitating coil deployment while preserving parent-vessel patency. This presentation introduces the FALCO Intracranial Stent and reviews its design characteristics, delivery profile, radiopacity, wall apposition, and compatibility with low-profile microcatheters. Initial clinical experience using a 2.5 × 20 mm FALCO Intracranial Stent for aneurysm embolization will be presented, with particular attention to device navigation, deployment, and support during the procedure. The procedural strategy, angiographic findings, and potential application of the device in small-caliber cerebral vessels will also be discussed, providing practical insights into stent-assisted treatment of anatomically challenging intracranial aneurysms.